This report demonstrates that expression of the P140A O 6 -methylguanine DNA methyl transferase (MGMT) mutant via retrovirus-mediated gene transfer leads to significant, but modest, resistance of cells to both 6-benzylguanine (6-BG) depletion and treatment with 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU). Expression of the P140A/G156A double mutant appeared to be associated with reduced or unstable protein in hematopoietic cells. Bone Marrow Transplantation (2000) 25, Suppl. 2, S105-S109.
Various mechanisms are involved in the repair of damaged DNA in mammalian cells. Among the best studied is the direct repair of DNA damage at the O 6 -position by O 6 -methylguanine DNA methyltransferase (MGMT). O 6 -methylguanine adducts are generated by a variety of chemotherapeutic agents and left unrepaired lead to cytotoxic DNA cross-links. 1 MGMT repairs the O 6 adduct prior to cross-link formation, thus protecting cells against cytotoxicity due to agents such as chloroethylnitrosoureas (CENUs). 2 MGMT functions by transferring the alkyl group from the O 6 position to a cysteine residue within the protein, after which the protein is no longer functional for repair. Due to this stochiometric reaction, cellular levels of MGMT correlate with resistance to agents which lead to cytotoxic O 6 -adducts. Recent studies have demonstrated increased MGMT activity in tumors compared to normal tissue. 3, 4 This increased expression of MGMT may be the basis of chemoresistance in the clinical setting. Conversely, normal bone marrow cells express low levels of MGMT. [5] [6] [7] Low level expression of MGMT may explain the delayed myelotoxicity associated with clinical use of CENUs. [8] [9] [10] Our laboratory and other investigators have demonstrated that over-expression of MGMT in hematopoietic cells is associated with acquisition of cellular resistance to CENUs. 7, [11] [12] [13] [14] [15] [16] [17] In our own studies, retroviral-mediated gene transfer of MGMT into reconstituting hematopoietic stem cells (HSC) led to protection of progenitors cells in vitro and in vivo from 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU). Animals infused with transduced cells survived otherwise lethal doses of BCNU with significantly less pancytopenia and immune deficiency compared to control mice. 7, 14, 15 One approach to improve the therapeutic window of CENUs is to concurrently deplete elevated MGMT activity in tumor cells pharmacologically, while increasing MGMT expression in normal cells using genetic approaches. In this regard, 6-benzylguanine (6-BG) which binds to and inactivates MGMT has been shown to deplete tumor cell MGMT activity and sensitize these cells to CENU treatment. [18] [19] [20] [21] [22] [23] [24] [25] In addition, several MGMT mutants and the bacterial analog, ada, have been shown to be resistant to inactivation by 6-BG. [26] [27] [28] [29] Thus, the combination of increased expression of 6-BG resistant MGMT in normal cells and depletion of tumor MGMT activity offers a potentially powerful approach to tumor therapy.
The application of genetic therapy approaches in human disease has focused to date primarily on hematopoietic cells. Hematopoietic stem cells, which give rise to all blood cells, are easily obtained, manipulated in vitro and can reestablish hematopoiesis when infused into a recipient animal. To date, however, gene transfer efficiency into hematopoietic stem cells of large animals have been low, limiting the clinical application of this technology. 30 In this study, we pursued the use of MGMT mutants to examine combined 6-BG and BCNU resistance in hematopoietic cells. We used retrovirus-mediated gene transfer to introduce wild-type (WT) MGMT and two MGMT mutants, proline → alanine at position 140 (P140A) and P140A plus glycine → alanine at position 156 (G156A), double mutant (P140A/G156A) into a hematopoietic cell line deficient in MGMT expression (L1210 cells) and primary murine hematopoietic cells. The P140A mutant has been reported to be approximately 20-fold more resistant to 6-BG inactivation compared to MGMT. 26 The double P140A/G156A mutant conferred 1200-fold more resistance to 6-BG than WT MGMT. 26 Both mutants have been previously characterized in non-hematopoietic uses.
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Materials and methods
Retroviral vectors
The WT MGMT cDNA, P140A and P140A/G156A mutant cDNAs were cloned into the Moloney stem cell virus (MSCV) as recently described. 17 The inserted MGMT cDNA was expressed from the 5Ј long terminal repeat (LTR). An internal phosphoglycerate kinase (PGK) promoter was used to express the neo phosphotransferase (neo) sequence conferring GA18 resistance. Stable retroviral producer clones were generated in GP+E86 cells 32 after selection of cells in 0.75 mg/ml G418 (dry powder, Gibco BRL, Gaithersburg, MD, USA). Clones were screened for viral titers as previously described. 33 All producer cells were maintained in Dulbecco's modified Eagle's medium (Gibco BRL) supplemented with 10% calf serum (CS) (Summit Biotechnology, Ft Collins, CO, USA) and 2% (v/v) penicillin-streptomycin (Gibco BRL) (P/S).
Transduction of cell lines and bone marrow
L1210 cells obtained from American Type Culture Collection (Rockville, MD, USA) were maintained in RPMI 1630 supplemented with 15% CS and P/S. Cells were infected on FN CH-296 (Retronectin; Takara Shuzo, Otsu, Japan) as previously described.
33 G418-resistant L1210 clones were grown in 0.6% agar (Difco Bacto-agar; Difco Laboratories, Detroit, MI, USA) and individual colonies picked and expanded. Primary bone marrow was harvested and transduced as previously described. 34 
Analysis of MGMT repair activity, expression and protein
Analysis of MGMT expression was carried out by Northern and Western analysis using standard methods. The probe for Northern blot was a 32 P-end-labeled EcoRI-XhoI MGMT cDNA fragment (of MSCV-MGMT), that was double gel purified. Western blot was performed with the MT3.1 monoclonal antibody (Chemicon International, Temecula, CA, USA) at a 1:200 dilution. MGMT activity assays were performed as previously described 35 and utilized cellular extracts incubated with a labeled 18-base pair DNA fragment containing a methylation-sensitive PvuII restriction site harboring a O 6 -methylguanine base. MGMT activity was associated with increased PvuII cutting and the generation of an 8 bp fragment.
Drug treatments
6-BG resistance was determined by incubating cells with 40 micromolar 6-BG (provided by Dr R Moschel, Frederick Cancer Research Institute, Frederick, MD, USA) for 1 h. Each sample was analyzed for residual MGMT activity as above. BCNU sensitivity was determined by incubation of cells with increasing concentrations of BCNU (Drug Synthesis and Chemistry Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD, USA) for 1 h at 37°C. Treated cells were washed, and survival assayed by plating in agar (for L1210 cells) or in standard progenitor assays in methycellulose (for bone marrow cells).
Results
Retroviral-mediated gene transfer and expression of MGMT
Retrovirus producer clones generated a recombinant titer of approximately 1 × 10 3 up to Ͼ1 × 10 5 G418 cfu/ml. Infected and G418-selected L1210 cells demonstrated equivalent levels of viral MGMT mRNA transcripts, while parenteral L1210 and L1210 cells infected with an empty MSCV virus lacked detectable MGMT mRNA transcripts in total cellular RNA assayed by Nothern blot. In spite of this mRNA MGMT expression, both the level of MGMT protein assayed by Western blot and MGMT repair activity, assayed in the oligo DNA assay, were reduced in cells expressing the P140A/G156A MGMT mutant (Figure 1 ). This difference in expressed MGMT protein levels was not specific to L1210 cells, since transduction of two other cell lines, B16 melanoma cells and Lewis lung carcinoma cells, yielded identical results. Levels of both protein and activity were similar in cells infected with retrovirus vectors expressing WTMGMT and the P140A MGMT mutant.
Thus expression of the P140A/G156A MGMT mutant did not protect against combined 6-BG and BCNU treatment (data not shown). In contrast, in vitro studies demonstrated that MGMT repair activity remained detectable after treatment with up to 40 micromolar 6-BG in L1210 cells expressing the P140A MGMT. MGMT repair activity was completely depleted above 5 micromolar 6-BG in cells expressing WT MGMT (Figure 2 ). This data correlated with maintenance of BCNU resistance in cell survival assays. While cells expressing WT MGMT showed increased resistance to BCNU in the absence of 6-BG pretreatment, sensitivity returned to the level of infected parenteral cells after pre-treatment with 20 micromolar 6-BG. In contrast, L1210 cells expressing P140A MGMT remained resistant to BCNU after 6-BG treatment ( Figure  3) .
Studies in primary murine hematopoietic cells yielded similar results. Expression of P140A MGMT was associated with a two-fold increase in inhibitory concentration IC 50 for BCNU even after pretreatment with 20 micromolar 6-BG. In contrast, the IC 50 after combined 6-BG and BCNU treatment of cells expressing WT MGMT is similar to control cells, while without 6-BG pretreatment these cells demonstrate a two-fold increase IC 50 to BCNU. 
Discussion
Increased resistance of tumor cells to CENU treatment is likely due, at least in part, to elevated levels of MGMT expression in these cells. In contrast, sensitivity of bone marrow cells and myelotoxicity which develops with the clinical use of CENUs is associated with low levels of MGMT expression in hematopoietic precursor cells. Our laboratory has exploited the use of recombinant retroviral vectors to over-express WT MGMT or MGMT mutants in hematopoietic cells.
The results of these studies show that hematopoietic cells can be made resistant to both 6-BG depletion and BCNU cytotoxicity if certain MGMT mutants are highly expressed. Although the increase in dual resistance is small, the resistance needed in vivo is not yet clear. In addition, several mutants have more recently been described which are significantly more resistant to 6-BG than P140A. For instance, Xu-Welliver et al 29 describe a P140K mutant of MGMT which is approximately 100-fold more resistant to 6-BG than the P140A MGMT. Thus further enhancement of the therapeutic window is possible using these newer mutants.
A surprising result of this study was the apparent lack of utility of the P140A/G156A double mutant. Hickson et al 31 have previously demonstrated that P140A/G156A protected cells against 6-BG inactivation and sensitization to metazolmide. However, these authors did observe a log reduction in repair activity of this mutant compared to WT MGMT. We hypothesize that the difference in the results reported here is due to difference in levels of expression between expression constructs utilized and cells analyzed. Since hematopoetic cells tend to express transgene constructs at low levels, newer retroviral backbones which enhance expression in these cells may prove useful. However, the strategy of dual 6-BG depletion and CENU resistance clearly holds promise for innovative future therapies. Given the sensitivity of HSC to these agents, it is likely that transdued cells will have a survival advantage in vivo. If so, selection of infrequent transduced stem cells may be possible in human clinical trials.
